TY - JOUR
T1 - The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis
AU - Frascoli, Federico
AU - Roos, Izanne
AU - Malpas, Charles B.
AU - Kalincik, Tomas
N1 - Funding Information:
FF acknowledges the support from the Australian Research Council discovery project grant DP180101512. IR is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. CM acknowledges support from a Research Fellowship from Multiple Sclerosis Research Australia. TK receives a NHMRC Early Career Fellowship, NHMRC Project Grants [1129789, 1157717] and Dame Kate Campbell Professorial Fellowship from the University of Melbourne. TK served on scientific advisory boards for BMS, Roche, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck. IR served on scientific advisory boards, received conference travel support and/or honoraria from Novartis, Merck, Biogen, Roche.
Funding Information:
FF acknowledges the support from the Australian Research Council discovery project grant DP180101512. IR is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. CM acknowledges support from a Research Fellowship from Multiple Sclerosis Research Australia. TK receives a NHMRC Early Career Fellowship, NHMRC Project Grants [1129789, 1157717] and Dame Kate Campbell Professorial Fellowship from the University of Melbourne.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/5/21
Y1 - 2022/5/21
N2 - Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for the response to disease modifying therapies is proposed. With a population approach and separate states for patients accounting for their risk of relapses, a system of nonlinear equations is formulated, similarly to established epidemiological models. Different parameters describe the effect of drugs and treatment switch in reducing the frequency of relapses. The model allows for a good fit to previously published data for experiments where different drugs are used. It also shows that different treatments maintain a high degree of similarity, with analogous dynamical features: a pre-treatment increment in relapse frequency leading to a distinct peak, a rapid drop after treatment switch and a plateau corresponding to a new base relapse activity, which seems dependant on the treatment chosen. A sensitivity analysis shows that the uncertainty in the initial proportions of different populations and the frequency of relapses can modify the overall dynamics of the response to treatment. Drugs are observed to induce effects that depend on patient sample's intrinsic characteristics, producing two clearly distinct and independent dynamics of relapse response. This confirms the clinical observation that certain drugs may be overall more successful in lowering the rate of relapses more significantly than others, notwithstanding the fact that patients behave differently across experiments.
AB - Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for the response to disease modifying therapies is proposed. With a population approach and separate states for patients accounting for their risk of relapses, a system of nonlinear equations is formulated, similarly to established epidemiological models. Different parameters describe the effect of drugs and treatment switch in reducing the frequency of relapses. The model allows for a good fit to previously published data for experiments where different drugs are used. It also shows that different treatments maintain a high degree of similarity, with analogous dynamical features: a pre-treatment increment in relapse frequency leading to a distinct peak, a rapid drop after treatment switch and a plateau corresponding to a new base relapse activity, which seems dependant on the treatment chosen. A sensitivity analysis shows that the uncertainty in the initial proportions of different populations and the frequency of relapses can modify the overall dynamics of the response to treatment. Drugs are observed to induce effects that depend on patient sample's intrinsic characteristics, producing two clearly distinct and independent dynamics of relapse response. This confirms the clinical observation that certain drugs may be overall more successful in lowering the rate of relapses more significantly than others, notwithstanding the fact that patients behave differently across experiments.
KW - Drug trials
KW - Multiple sclerosis
KW - Population models
UR - http://www.scopus.com/inward/record.url?scp=85126523048&partnerID=8YFLogxK
U2 - 10.1016/j.jtbi.2022.111091
DO - 10.1016/j.jtbi.2022.111091
M3 - Article
C2 - 35283184
AN - SCOPUS:85126523048
SN - 0022-5193
VL - 541
JO - Journal of Theoretical Biology
JF - Journal of Theoretical Biology
M1 - 111091
ER -